Pure red blood cell aplasia. Extremely rare, but a potential side effect of the epo drugs. It remains on the market because of the risk benefit ratio. This applies to those in renal failure and on chemo so weak they can't function. It it were indicated for performance enhancement, it would not be in any way worth the risk, however small.
http://www.emedicine.com/med/topic1967.htm